Literature DB >> 19761098

Model selection for time-activity curves: the corrected Akaike information criterion and the F-test.

Peter Kletting1, Gerhard Glatting.   

Abstract

Data analysis often requires a multi model approach, i.e. the best model or models are selected from a well chosen set of candidate models and subsequent parameter inference is conducted. The selection of the model or models which are best supported by the data can be accomplished using various criteria. The present work focuses on the comparison of two approaches namely the corrected Akaike information criterion (AICc) and the F-test for sparse data sets, which are common in medical research. The selection of the true model and the determination of relevant pharmacokinetic parameters as the clearance, the volume of distribution and the mean residence time are examined using Monte Carlo simulations with 10000 replications. The data (N = 10 per replication) are generated from a sum of two exponentials, which parameters were determined by fitting to time-concentration data of 111In labelled anti-CD66 antibody in blood serum. Four different normal distributed multiplicative statistical errors (0.05, 0.1, 0.15, 0.2) were examined. The set of candidate models consists of sums of up to 3 exponentials. Comparisons with two different model set sizes were conducted. All candidate models are fitted to the generated data and selected according to the AICc and the F-test. Both selection criteria perform well for our data. The selection frequency of functions of lower dimension increases proportionally to the statistical error for both criteria, while for higher errors, the AICc tends to choose a model of lower dimension more frequently than the F-test. In addition, the overfitted fraction decreases proportionally to the statistical error for both methods but selection frequency of function of higher dimension is larger using the F-test. The choice of the adequate model set is important for the positive effect of model averaging concerning the bias and the variability of the estimated parameters. It is in general assumed and has been confirmed in this study that parameter estimation using the AICc has clear advantages over the F-test.

Mesh:

Year:  2009        PMID: 19761098     DOI: 10.1016/j.zemedi.2009.05.003

Source DB:  PubMed          Journal:  Z Med Phys        ISSN: 0939-3889            Impact factor:   4.820


  14 in total

1.  Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.

Authors:  Luisa F Escobar-Hoyos; Alex Penson; Ram Kannan; Hana Cho; Chun-Hao Pan; Rohit K Singh; Lisa H Apken; G Aaron Hobbs; Renhe Luo; Nicolas Lecomte; Sruthi Babu; Fong Cheng Pan; Direna Alonso-Curbelo; John P Morris; Gokce Askan; Olivera Grbovic-Huezo; Paul Ogrodowski; Jonathan Bermeo; Joseph Saglimbeni; Cristian D Cruz; Yu-Jui Ho; Sharon A Lawrence; Jerry P Melchor; Grant A Goda; Karen Bai; Alessandro Pastore; Simon J Hogg; Srivatsan Raghavan; Peter Bailey; David K Chang; Andrew Biankin; Kenneth R Shroyer; Brian M Wolpin; Andrew J Aguirre; Andrea Ventura; Barry Taylor; Channing J Der; Daniel Dominguez; Daniel Kümmel; Andrea Oeckinghaus; Scott W Lowe; Robert K Bradley; Omar Abdel-Wahab; Steven D Leach
Journal:  Cancer Cell       Date:  2020-06-18       Impact factor: 31.743

2.  Statistical properties of sleep-wake behavior in the rat and their relation to circadian and ultradian phases.

Authors:  Richard Stephenson; Svetlana Famina; Aimee M Caron; Joonbum Lim
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

3.  Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue.

Authors:  Michel Koole; June van Aalst; Martijn Devrome; Nathalie Mertens; Kim Serdons; Brigitte Lacroix; Joel Mercier; David Sciberras; Paul Maguire; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-18       Impact factor: 9.236

4.  Experimental solubility and modeling of Crizotinib (anti-cancer medication) in supercritical carbon dioxide.

Authors:  Gholamhossein Sodeifian; Chandrasekhar Garlapati; Armin Roshanghias
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

5.  Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input.

Authors:  Sudheer D Rani; Samuel T Nemanich; Nicole Fettig; Kooresh I Shoghi
Journal:  Nucl Med Biol       Date:  2013-02-28       Impact factor: 2.408

6.  Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders.

Authors:  Raj K Kalapatapu; Daniel F Lewis; Sophia Vinogradov; Steven L Batki; Theresa Winhusen
Journal:  J Addict Dis       Date:  2013

7.  Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.

Authors:  Peter Kletting; Christian Maaß; Sven Reske; Ambros J Beer; Gerhard Glatting
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

8.  Model selection criteria for dynamic brain PET studies.

Authors:  Sandeep S V Golla; Sofie M Adriaanse; Maqsood Yaqub; Albert D Windhorst; Adriaan A Lammertsma; Bart N M van Berckel; Ronald Boellaard
Journal:  EJNMMI Phys       Date:  2017-12-06

9.  EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations.

Authors:  Jonathan I Gear; Maurice G Cox; Johan Gustafsson; Katarina Sjögreen Gleisner; Iain Murray; Gerhard Glatting; Mark Konijnenberg; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-14       Impact factor: 9.236

10.  Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.

Authors:  Peter Kletting; Christiane Schuchardt; Harshad R Kulkarni; Mostafa Shahinfar; Aviral Singh; Gerhard Glatting; Richard P Baum; Ambros J Beer
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.